In a report released today, Ryan Sigdahl from Craig-Hallum maintained a Buy rating on Neurogene. The company’s shares closed yesterday at $25.83.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Sigdahl is a 5-star analyst with an average return of 11.8% and a 46.45% success rate. Sigdahl covers the Consumer Cyclical sector, focusing on stocks such as Flutter Entertainment PLC, Super Group (SGHC), and Inspired Entertainment.
Neurogene has an analyst consensus of Strong Buy, with a price target consensus of $53.67, a 107.78% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $45.00 price target.
The company has a one-year high of $74.49 and a one-year low of $6.88. Currently, Neurogene has an average volume of 152K.
Read More on NGNE:
Disclaimer & DisclosureReport an Issue
- Neurogene’s Favorable Position in CNS Gene Therapy: Buy Rating Backed by Strategic Advantages and Competitive Valuation
- Neurogene Completes FDA Talks for Rett Syndrome Trial
- Neurogene completes FDA discussion on Embolden trial, announces NGN-401 data
- Neurogene’s Strategic Advantage and Undervaluation: A Buy Recommendation with a $45 Target
- Neurogene looks ‘deeply undervalued’ after Taysha news, says H.C. Wainwright
/Semiconductor%20Chip%20by%20Gorodenkoff%20via%20Shutterstock.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)